How Epstein–Barr virus alters cell RNA processing to help it spread
Programmed splicing derangement as new EBV host cell shut-off mechanism
This project looks at how Epstein–Barr virus changes the way human cells edit their RNA, which may explain why the virus contributes to cancers and autoimmune problems—especially in people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11299488 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers are studying how EBV (Epstein–Barr virus) forces human cells to change their RNA splicing and shut down normal cell messages during viral replication. They will examine infected human cells and clinical samples, and use molecular lab tests to track which host RNAs are altered when the virus becomes active. The team will compare changes seen during EBV lytic activity with samples from people at higher risk, such as those living with HIV, to connect the molecular events to disease outcomes. Ultimately the work aims to point to specific viral or host steps that could be targeted to reduce EBV-driven cancers or autoimmune effects.
Who could benefit from this research
Good fit: Ideal candidates would be people living with HIV or patients with suspected EBV-associated cancers or autoimmune conditions who can provide blood or tumor tissue samples.
Not a fit: People without evidence of EBV involvement in their condition or whose illnesses are unrelated to EBV are unlikely to receive direct benefit from this research.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets to prevent or treat EBV-associated cancers and autoimmune complications, particularly for people with HIV.
How similar studies have performed: Previous research has shown viruses can shut off host gene expression and that EBV lytic activity links to cancers, but the specific programmed splicing derangement mechanism described here is relatively new.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Flemington, Erik K — Tulane University of Louisiana
- Study coordinator: Flemington, Erik K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.